Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates
10:31am, Friday, 19'th Dec 2025
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.77 per share a year ago.
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
08:05am, Friday, 19'th Dec 2025
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK)
02:00am, Thursday, 11'th Dec 2025
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Barinthus Biotherapeutics (NASDAQ: BRNS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of “Hold” by Analysts
01:10am, Monday, 08'th Dec 2025
Shares of Oncobiologics, Inc. (NASDAQ: OTLK - Get Free Report) have been given an average rating of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. One investme
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
09:05am, Monday, 24'th Nov 2025
ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
08:30am, Thursday, 13'th Nov 2025
ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
08:35am, Monday, 03'rd Nov 2025
ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Provides Update on Type A Meeting with FDA
08:45am, Monday, 29'th Sep 2025
ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment o
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
08:35am, Wednesday, 03'rd Sep 2025
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of
Outlook Therapeutics Requests Type A Meeting with FDA
08:35am, Tuesday, 02'nd Sep 2025
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
11:41am, Friday, 29'th Aug 2025
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug
11:51am, Thursday, 28'th Aug 2025
Shares of Outlook Therapeutics fell sharply on Thursday after the US Food and Drug Administration (FDA) rejected the company's application for its experimental eye drug ONS-5010, a proposed treatment
FDA Rejects Outlook Therapeutics Eye Drug For Second Time
11:15am, Thursday, 28'th Aug 2025
Outlook Therapeutics, Inc. OTLK stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.
US FDA declines to approve Outlook Therapeutics' drug for eye condition
06:39am, Thursday, 28'th Aug 2025
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' experimental drug to treat a type of eye condition that causes blurred vision, the company said on Thursday.
ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
